73 results about "Diabetes insipidus" patented technology

This invention provides novel compounds according to general formula (1) wherein A is a bicyclic or tricyclic azepine derivative, V1 and V2 are both H, OMe or F, or one of V1 and V2 is Br, Cl, F, OH, OMe, OBn, OPh, O-acyl, N3, NH2, NHBn or NH-acyl and the other is H, or V1 and V2 together are ═O, —O(CH2)pO— or —S(CH2)pS—; W1 is either O or S; X1 and X2 are both H, or together are ═O or ═S; Y is OR5 or NR6R7; R1, R2, R3 and R4 are independently selected from H, lower alkyl, lower alkyloxy, F, Cl and Br; R5 is selected from H and lower alkyl; R6 and R7 are independently selected from H and lower alkyl, or together are —(CH2)n—; n=3, 4, 5, 6; and p is 2 or 3. The compounds are agonists at the vasopressin V2 receptor and are useful as antidiuretics and procoagulants. The invention further comprises pharmaceutical compositions incorporating these vasopressin agonists, which compositions are particularly useful in the treatment of central diabetes insipidus, nocturnal enuresis and nocturia.

Disclosed are devices for urine voiding postponement, and methods for treating conditions such as central diabetes insipidus, enuresis, nocturia, urinary frequency or incontinence. The devices deliver a desmopressin flux through the skin of a patient in a low dose amount just necessary to achieve a desired anti-diuretic effect without undesirable side effects such as hyponatremia. The devices are designed to permit a state of normal urinary production to return quickly after the desmopressin flux is terminated.

Disclosed is a family of intranasal spray dispensers for administering uniform low doses of desmopressin so as to achieve safe antidiuresis in human patients. The dispensers of the invention may be used in the treatment of nocturia, primary nocturnal enuresis, incontinence, urinary frequency, diabetes insipidus, or any disease or syndrome where desmopressin therapy is useful or where safe temporary suppression of urine production may lead to beneficial health effects or increased convenience in voiding control.

The present invention is directed to the use of a compound stimulating deubiquitinating activity in a cell for the manufacture of a medicament for enhancing the expression of integral membrane proteins on the cell surface. Especially, the invention is directed to the use of such compound for the manufacture of a medicament for the treatment of a disease of condition selected from the group consisting of cystic fibrosis, diabetes insipidus, hypercholesterinaemia and long QT-syndrome-2.

4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepine derivatives, which have excellent arginine vasopressin V2 activity and are useful for a drug for the treatment of central diabetes insipidus and / or nocturia.

The invention relates to a traditional Chinese medicine for curing diabetes insipidus. The traditional Chinese medicine is characterized by mainly comprising the following Chinese medical herbs: 10 g of wolferry fruit, 10 g glossy privet fruit, 10 g Korean raspberry, 10 g Chinese dodder, 6 g of magnolia vine fruit, 12 g of crude radix dioscoreae, 15 g of prepared rehmannia root, 6 g of achyranthes root, 10 g of bupleurum root, 9 g of pulp of dogwood fruit, 10 g of Erdong, 6 g of Zhibai, 12 g of calcined oyster shell and 10 g of mantis egg-case. The preparation method of the traditional Chinese medicine comprises the following steps: the Chinese medical herbs are put in a vessel to be soaked with water for 30 minutes, boiled with mild fire for 30 minutes and then filtered to obtain 150 ml of decoction, and the decoction is taken after supper and by one dose per day; and 5 dosages are taken as one period of treatment. The preparation is prepared from the pure Chinese medical herbs by a traditional preparation method, and the traditional Chinese medicine retains the medicinal properties, has the effects of enriching yin, tonifying kidney and stopping metrorrhagia, achieves the purpose of curing the diabetes insipidus and has no side effect.

The present invention provides a novel 4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepine derivative or a pharmaceutically acceptable salt thereof, which can be used as a therapeutic Or an agent for the prevention of nocturnal frequency and / or diabetes insipidus.

The invention discloses an oral administration pharmaceutical composition for treating diabetes insipidus, wherein the active constituents include the following raw material herbs (by weight portion): wolfberry fruit 10g, raspberry 10g, doddor seed 10g, schisandra fruit 6g, Chinese yam 12g, prepared rhizome of rehmannia 15g, pulp of dogwood fruit 9g, oyster 12g, ootheca rubra 10g, bitter cardamom 9g and poria cocos wolf 25g. The medicament should be decocted in water for the oral dose.